Managing diabetes during pregnancy just got a whole lot clearer—and potentially more controversial. A groundbreaking international consensus statement has emerged, offering the first-ever guidelines specifically tailored to using diabetes technology during pregnancy for women with type 1 diabetes (T1D), type 2 diabetes (T2D), or gestational diabetes (GD). But here's where it gets controversial: while the evidence is strongest for T1D, the statement also provides recommendations for T2D and GD, despite acknowledging the need for more research. Is this a bold step forward or a leap of faith?
Organized by the diaTribe Foundation, this comprehensive document combines available evidence with expert opinions from a global panel of specialists in endocrinology, diabetes technology, obstetrics, and gynecology. Lead author Dr. Katrien Benhalima, from the Department of Endocrinology at University Hospitals Leuven, Belgium, emphasizes its practical focus: ‘I hope it will be used hands-on, providing clear guidance for both healthcare providers and women on how to leverage technology for informed decision-making.’ And this is the part most people miss: while the recommendations are evidence-based for T1D, those for T2D and GD rely heavily on expert opinion, as research in these areas is still catching up.
The statement boldly recommends Continuous Glucose Monitoring (CGM) and Automated Insulin Delivery (AID) systems for women with T1D during preconception and pregnancy. For T2D, capillary blood glucose measurement is the primary recommendation, though CGM is suggested as an option. Similarly, for GD, capillary glucose testing is advised, with CGM offered based on availability. The document also includes detailed tables of AID systems and settings for intrapartum and postpartum care, ensuring a holistic approach.
One critical—and potentially divisive—point is the emphasis on sensor quality control. ‘Some sensors come from countries with less stringent quality standards, which can pose risks,’ Dr. Benhalima warns. ‘We strongly recommend using only rigorously tested sensors.’ This raises questions about global access and equity, as CGM technology remains unavailable in many parts of the world, even for T1D.
Endorsed by leading organizations like the American Association of Clinical Endocrinology, the European Association for the Study of Diabetes (EASD), and the International Diabetes Federation, the statement has garnered widespread support. Yet, it also highlights the need for future research to address global disparities in technology access. Dr. Anne L. Peters, a professor at the University of Southern California, praises the document as ‘a good summary of current data, pushing for broader CGM and AID use in pregnancy.’ But she also underscores the ongoing challenges in implementation.
So, here’s the question: Is this consensus statement a game-changer for diabetes management in pregnancy, or does it raise more questions than it answers? With its mix of evidence-based and opinion-driven recommendations, it’s sure to spark debate. What’s your take? Do you think the guidelines go too far in areas with limited research, or are they a necessary step to improve care? Let’s discuss in the comments!
